Treatment allocation in controlled trials: Why randomise?

BMJ

Volumn 318, Issue 7192, 1999, Pages 1209-

  Altman, Douglas G ^a   Bland, Martin J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TREATMENT OUTCOME; METHODOLOGY; PATIENT SELECTION; REVIEW;

PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS;

EID: 0033128807     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.318.7192.1209     Document Type: Article

References (7)

1. Altman D.G., Randomisation.BMJ 1991; 302:1481–1482.
2. Sacks H., Chalmers T.C., Smith H., Randomized versus historical controls for clinical trials. Am J Med 1982; 72:233–240.
3. Smithells R.W., Sheppard S., Schorah C.J., Seller M.J., Nevin N.C., Harris R., et al. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1980; i:339–340.
4. MRC Vitamin Study Research Group.Prevention of neural tube defects: results of the Medical Research Council vitamin study. Lancet 1991; 338:131–137.
5. Medical Research Council.Streptomycin treatment of pulmonary tuberculosis. BMJ 1948; 2:769–782.
6. Black N., Why we need observational studies to evaluate the effectiveness of health care.BMJ 1996; 312:1215–1218.
7. Begg C., Cho M., Eastwood S., Horton R., Moher D., Olkin I., et-al. Improving the quality of reporting of randomized controlled trials: the CONSORT Statement. JAMA 1996; 276:637–639.